Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458405 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
A Phase 1 study, sponsored by Capricor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT01458405 is a Phase 1 study that was terminated before completion, run by Capricor. The registered enrollment target is 135 participants.
The verdict
NCT01458405, a Phase 1 study, was terminated before completion, sponsored by Capricor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
Interventions
- DRUG Placebo
- BIOLOGICAL CAP-1002 Allogeneic Cardiosphere-Derived Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2012-11-13 |
| Est. Completion | 2019-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458405
The ClinicalTrials.gov registry entry for NCT01458405 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01458405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01458405 about?
NCT01458405 is a clinical study titled "Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration". The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
What is the current status of trial NCT01458405?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2012-11-13. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT01458405?
The interventions under investigation include: Placebo (DRUG), CAP-1002 Allogeneic Cardiosphere-Derived Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01458405?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.